In more than 70 countries, Médecins Sans Frontières provides medical humanitarian assistance to save lives and ease the suffering of people in crisis situations.
We set up the MSF Access Campaign in 1999 to push for access to, and the development of, life-saving and life-prolonging medicines, diagnostic tests and vaccines for people in our programmes and beyond.
Based in Paris, CRASH conducts and directs studies and analysis of MSF actions. They participate in internal training sessions and assessment missions in the field.
Based in Geneva, UREPH (or Research Unit) aims to improve the way MSF projects are implemented in the field and to participate in critical thinking on humanitarian and medical action.
Based in Brussels, MSF Analysis intends to stimulate reflection and debate on humanitarian topics organised around the themes of migration, refugees, aid access, health policy and the environment in which aid operates.
This logistical and supply centre in Brussels provides storage of and delivers medical equipment, logistics and drugs for international purchases for MSF missions.
This supply and logistics centre in Bordeaux, France, provides warehousing and delivery of medical equipment, logistics and drugs for international purchases for MSF missions.
This logistical centre in Amsterdam purchases, tests, and stores equipment including vehicles, communications material, power supplies, water-processing facilities and nutritional supplements.
BRAMU specialises in neglected tropical diseases, such as dengue and Chagas, and other infectious diseases. This medical unit is based in Rio de Janeiro, Brazil.
Our medical guidelines are based on scientific data collected from MSF’s experiences, the World Health Organization (WHO), other renowned international medical institutions, and medical and scientific journals.
Providing epidemiological expertise to underpin our operations, conducting research and training to support our goal of providing medical aid in areas where people are affected by conflict, epidemics, disasters, or excluded from health care.
Evaluation Units have been established in Vienna, Stockholm, and Paris, assessing the potential and limitations of medical humanitarian action, thereby enhancing the effectiveness of our medical humanitarian work.
MSF works with LGBTQI+ populations in many settings over the last 25-30 years. LGBTQI+ people face healthcare disparities with limited access to care and higher disease rates than the general population.
The Luxembourg Operational Research (LuxOR) unit coordinates field research projects and operational research training, and provides support for documentation activities and routine data collection.
The MSF Paediatric Days is an event for paediatric field staff, policy makers and academia to exchange ideas, align efforts, inspire and share frontline research to advance urgent paediatric issues of direct concern for the humanitarian field.
The MSF Foundation aims to create a fertile arena for logistics and medical knowledge-sharing to meet the needs of MSF and the humanitarian sector as a whole.
A collaborative, patients’ needs-driven, non-profit drug research and development organisation that is developing new treatments for neglected diseases, founded in 2003 by seven organisations from around the world.
The MSF Science Portal is a digital platform for Médecins Sans Frontières to share the medical evidence we gather as part of our medical humanitarian work aiding people and communities affected by conflict, epidemics, disasters, or exclusion from health services.
Doctors Without Borders/Médecins Sans Frontières (MSF) has launched the Transformational Investment Capacity (TIC) to transform our ability to address the most pressing medical and humanitarian challenges around the world.
The Telemedicine program provides secure solutions designed to support the needs of healthcare professionals across MSF, while building a community of knowledge-sharing and clinical collaboration.
Launched in 2012, the MSF Sweden Innovation Unit deploys a human-centered approach for promoting a culture of innovation within MSF, in order to more effectively co-create innovations that save lives and alleviate suffering.
Warning: Undefined variable $active_link in Drupal\msf_navigation\Plugin\Block\IARSectionNavBlock->build() (line 100 of modules/custom/msf_navigation/src/Plugin/Block/IARSectionNavBlock.php).
The Ebola response in the Democratic Republic of Congo
The Sahel: Civilians trapped in a deadly spiral of violence
Less than human: How Europe’s policies harm refugees, migrants and asylum seekers
Access Campaign: 20 years of advocacy in action
2019 in figures
Regions
Africa
Asia & Pacific
Europe & Central Asia
The Americas
Middle East & North Africa
by
Michelle French
Médecins Sans Frontières medical teams have long faced challenges in getting effective and affordable treatments for people in our care. In the late 1990s, as frustration mounted over people dying from treatable diseases, MSF began to document the problem, joining with patient groups to speak out forcefully and demand action.
In 1999, MSF publicly launched the Campaign for Access to Essential Medicines, now the Access Campaign, to tackle the policies, and the legal and political barriers, that prevent people from accessing treatment in the communities where we work and beyond. That same year, MSF was awarded the Nobel Peace Prize and put the funds towards improving treatments and boosting research for neglected diseases, merging with the Campaign’s work.
At the time, the HIV/AIDS epidemic was still raging across the world. While lifesaving antiretroviral medicines had transformed HIV into a manageable chronic condition in wealthy countries, treatment was priced out of reach for almost everyone else. In addition, treatments for neglected diseases such as tuberculosis, malaria and sleeping sickness were often ineffective, toxic, ill-adapted for use in the places we work, or simply did not exist at all.
For 20 years, MSF has worked with civil society to ensure that pharmaceutical corporations, governments and others prioritise people’s lives and health over patents and profits. The access to medicines movement overcame patent monopolies to make way for generic production and competition of antiretrovirals, and prices dropped 99 per cent over 10 years. This and other achievements of the Campaign, including for hepatitis C, malaria, pneumonia, sleeping sickness and TB, are highlighted below.
But many new drugs, diagnostics and vaccines are being sold at increasingly high prices, and monopolies are becoming more entrenched. We are still missing the tools we need to control rising antimicrobial resistance and outbreaks of epidemic diseases such as Ebola and COVID-19. MSF, through the Access Campaign, continues to advocate the transformation of the medical innovation ecosystem to better address the health needs of people in our care. For example, given that medical research and development is heavily financed by governments, MSF is calling for increased transparency in drug development and production costs, and a larger role for the public in making sure that medicines are made affordable and accessible.
The crisis of access to medicines and innovation is no longer affecting only low- and middle-income countries; it is now truly global. Our slogan, Medicines Shouldn’t Be a Luxury, is still valid; together we must drastically step up efforts to expand people’s access to lifesaving health tools.
1999
Launch
MSF launches the Campaign for Access to Essential Medicines to improve access to treatment and spur needed medical research.
2000
TB
MSF helps bring down exorbitant prices for five key drugs used to treat drug-resistant tuberculosis.
A landmark $1-a-day price for HIV medicines, publicly offered to MSF, boosts political will to treat HIV/AIDS in low- and middle-income countries.
The atmosphere in the hospital where we were treating sleeping sickness was very tense because one in twenty of the patients who came to us died simply from the toxicity of the treatment. That’s been my fight ever since, for more than 35 years, to try to bring something better for those patients.Dr Bernard Pecoul, MSF Access Campaign’s first executive director
MSF and partners create the Drugs for Neglected Diseases initiative (DNDi), a non-profit that has since delivered eight new treatments.
2005
Trade
MSF stands with India to defend low- and middle-income countries’ rights to protect access to affordable medicines in trade pacts and patent laws.
2006
HIV/IP
For the first time, MSF supports a legal challenge to a patent, for HIV drug tenofovir, to increase access to lower-priced generic medicines.
We did everything we could, we shamed the company (Novartis), we went to shareholder meetings, we marched against them, we delivered petitions. I remember being so big and pregnant, and it being so hot, and we were all marching toward the court, and we were so determined. The only thing that we had were our voices. Leena Menghaney, lawyer, MSF Access Campaign, India
Europe! Hands Off Our Medicine! MSF campaigns to remove provisions from the EU-India trade pact that would block access to medicines.
2013
TB
An MSF doctor and an extensively drug-resistant tuberculosis survivor deliver their Test Me, Treat Me DR-TB Manifesto petition to the 2014 World Health Assembly.
We were always desperately seeking a cure everywhere. Some people were bragging to me about getting (the new) treatment in Singapore for $10,000 or in Vietnam for $8,000. If I wanted to have treatment, I would need to sell my house. So, I decided to wait and if I died, well at least my kids would be left with the house. I am very grateful to now have this cure from MSF. It gives hope to my children and the chance to see their father's face when they are grown up. Din Savorn, police officer, now cured of hepatitis C, Phnom Penh, Cambodia
The West Africa Ebola outbreak spurs research and development (R&D) into vaccines and treatments; MSF later supports clinical trials and pushes for affordable, accessible tools.